Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma
CONCLUSION: The RP2D is nab-paclitaxel 200 mg/m2 on day 1, combined with cisplatin 75 mg/mg2 on day 1 and capecitabin1000 mg/m2 on days 1-14, twice a day, every 3 weeks, for three cycles as an IC regimen prior to CCRT.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04850235.PMID:38135184 | DOI:10.1016/j.radonc.2023.110051 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - December 22, 2023 Category: Radiology Authors: None Yu-Chen Mei-Juan Luo Rong-Ping Liu Jing Jin Sheng-Wen Deng Lin-Quan Tang Xiao-Yun Li Li-Ting Liu Dong-Hua Luo Rui Sun Sai-Lan Liu Ji-Bin Li Qing Liu Pan Wang Qiu-Yan Chen Hai-Qiang Mai Shan-Shan Guo Source Type: research
Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma
CONCLUSION: The RP2D is nab-paclitaxel 200 mg/m2 on day 1, combined with cisplatin 75 mg/mg2 on day 1 and capecitabin1000 mg/m2 on days 1-14, twice a day, every 3 weeks, for three cycles as an IC regimen prior to CCRT.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04850235.PMID:38135184 | DOI:10.1016/j.radonc.2023.110051 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - December 22, 2023 Category: Radiology Authors: None Yu-Chen Mei-Juan Luo Rong-Ping Liu Jing Jin Sheng-Wen Deng Lin-Quan Tang Xiao-Yun Li Li-Ting Liu Dong-Hua Luo Rui Sun Sai-Lan Liu Ji-Bin Li Qing Liu Pan Wang Qiu-Yan Chen Hai-Qiang Mai Shan-Shan Guo Source Type: research
Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer
CONCLUSION: Camrelizumab combined with albumin-bound paclitaxel as the third- or later-line regimen greatly prolonged PFS and OS of advanced NSCLC patients. A prospective clinical trial is warranted.PMID:38124737 | PMC:PMC10731289 | DOI:10.3389/fimmu.2023.1278573 (Source: Cancer Control)
Source: Cancer Control - December 21, 2023 Category: Cancer & Oncology Authors: Jianfeng Zhu Yanyan Yu Jiaqi Mei Shiyao Chen Jiufei Li Sicong Jiang Source Type: research
Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial
EClinicalMedicine. 2023 Oct 24;65:102274. doi: 10.1016/j.eclinm.2023.102274. eCollection 2023 Nov.ABSTRACTBACKGROUND: Sintilimab is an antibody against programmed cell death protein 1. We assessed the efficacy and safety of sintilimab plus albumin-bound (nab)-paclitaxel for the treatment of recurrent or metastatic cervical cancer.METHODS: This multicenter, open-label, single-arm, phase II study (ClinicalTrials.gov identifier NCT04341883) enrolled patients with recurrent or metastatic cervical cancer who progressed after at least one line of systemic therapy. The patients received sintilimab 200 mg and nab-paclitaxel 260 mg...
Source: Cancer Control - December 18, 2023 Category: Cancer & Oncology Authors: Yin Wang Jing Zhao Haixi Liang Junxiu Liu Shenjiao Huang Guorong Zou Xin Huang Chunyan Lan Source Type: research
Long ‑term survival of a patient with advanced lung cancer treated with targeted therapy and anti‑PD‑1 immunotherapy as multi‑line therapy: A case report
In conclusion, the present case demonstrated the efficacy of targeted therapy and anti-PD-1 immunotherapy for the treatment of advanced lung cancer following the occurrence of drug resistance and progressive disease.PMID:38108071 | PMC:PMC10722554 | DOI:10.3892/ol.2023.14166 (Source: Oncology Letters)
Source: Oncology Letters - December 18, 2023 Category: Cancer & Oncology Authors: Tianhao Guo Wenjian Zhu Shuoqi Zhao Wenli Qiu Yan Wu Xuan Li Fei Ke Haibo Cheng Source Type: research
Cancers, Vol. 15, Pages 5801: Multisite Is Superior to Single-Site Intratumoral Chemotherapy to Retard the Outcomes of Pancreatic Ductal Adenocarcinoma in a Murine Model
Conclusions: Multisite intratumoral therapy in tandem with systemic treatment holds promise for reducing the tumor size and enhancing the overall survival in LAPC. (Source: Cancers)
Source: Cancers - December 11, 2023 Category: Cancer & Oncology Authors: Janette Lazarovits Ron Epelbaum Jesse Lachter Yaron Amikam Jacob Ben Arie Tags: Article Source Type: research
Cancers, Vol. 15, Pages 5753: Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity Testing
This study strongly supports the importance and value of PDX models for improvement in therapies of PC. (Source: Cancers)
Source: Cancers - December 8, 2023 Category: Cancer & Oncology Authors: Diana Behrens Ulrike Pfohl Theresia Conrad Michael Becker Bernadette Brzezicha Britta B üttner Silvia Wagner Cora Hallas Rita Lawlor Vladimir Khazak Michael Linnebacher Thomas Wartmann Iduna Fichtner Jens Hoffmann Mathias Dahlmann Wolfgang Walther Tags: Article Source Type: research
Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer
ConclusionCamrelizumab combined with albumin-bound paclitaxel as the third- or later-line regimen greatly prolonged PFS and OS of advanced NSCLC patients. A prospective clinical trial is warranted. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - December 6, 2023 Category: Allergy & Immunology Source Type: research
Correction: albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis
(Source: Journal of Experimental and Clinical Cancer Research)
Source: Journal of Experimental and Clinical Cancer Research - November 23, 2023 Category: Cancer & Oncology Authors: Shanqiang Qu, Songtao Qi, Huayang Zhang, Zhiyong Li, Kaicheng Wang, Taichen Zhu, Rongxu Ye, Wanghao Zhang, Guanglong Huang and Guo-zhong Yi Tags: Correction Source Type: research
Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real −world retrospective study
ConclusionNeoadjuvant PD-1 inhibitors combined with chemotherapy are feasible and safe, with a high pathological response and possible organ preservation in oral or oropharyngeal squamous cell carcinoma. However, further studies with a larger cohort of patients and longer follow-up period is required to strengthen our findings and evaluate the survival benefits of the treatment. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - November 14, 2023 Category: Allergy & Immunology Source Type: research
Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study
CONCLUSION: Second-line camrelizumab combined apatinib and chemotherapy might serve as a potential treatment with acceptable safety in patients with advanced LUAD.PMID:37956490 | DOI:10.1016/j.intimp.2023.111147 (Source: International Immunopharmacology)
Source: International Immunopharmacology - November 13, 2023 Category: Allergy & Immunology Authors: Yiwei Yao Yong Wang Yingying Du Fengshou Jiang Hui Liang Minghong Bi Hua Xie Wanren Peng Yueyin Pan Source Type: research
Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study
CONCLUSION: Second-line camrelizumab combined apatinib and chemotherapy might serve as a potential treatment with acceptable safety in patients with advanced LUAD.PMID:37956490 | DOI:10.1016/j.intimp.2023.111147 (Source: International Immunopharmacology)
Source: International Immunopharmacology - November 13, 2023 Category: Allergy & Immunology Authors: Yiwei Yao Yong Wang Yingying Du Fengshou Jiang Hui Liang Minghong Bi Hua Xie Wanren Peng Yueyin Pan Source Type: research
Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study
CONCLUSION: Second-line camrelizumab combined apatinib and chemotherapy might serve as a potential treatment with acceptable safety in patients with advanced LUAD.PMID:37956490 | DOI:10.1016/j.intimp.2023.111147 (Source: International Immunopharmacology)
Source: International Immunopharmacology - November 13, 2023 Category: Allergy & Immunology Authors: Yiwei Yao Yong Wang Yingying Du Fengshou Jiang Hui Liang Minghong Bi Hua Xie Wanren Peng Yueyin Pan Source Type: research
Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study
CONCLUSION: Second-line camrelizumab combined apatinib and chemotherapy might serve as a potential treatment with acceptable safety in patients with advanced LUAD.PMID:37956490 | DOI:10.1016/j.intimp.2023.111147 (Source: International Immunopharmacology)
Source: International Immunopharmacology - November 13, 2023 Category: Allergy & Immunology Authors: Yiwei Yao Yong Wang Yingying Du Fengshou Jiang Hui Liang Minghong Bi Hua Xie Wanren Peng Yueyin Pan Source Type: research
